Dr. Marasco on Engineering CAR T Cells

Video

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Wayne A. Marasco, MD, PhD, professor of medicine at Harvard Medical School, and principal investigator of cancer immunology and virology at Dana-Farber Cancer Institute, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Traditionally, monoclonal antibodies are made with high affinity and high specificity to ensure maximum potency. Conversely, CAR T cells often have to be reverse engineered to decrease their potency.

The affinity of CAR T cells must be downregulated to find a “sweet spot” so that the CAR T cells can recognize a protein that is overexpressed on the tumor cell and not that of a normal cell.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.